{"brief_title": "Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer", "brief_summary": "The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.", "condition": ["Carcinoma, Non-Small-Cell Lung"], "intervention_type": ["Drug"], "intervention_name": ["Sunitinib"], "description": ["Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity."], "arm_group_label": ["1"], "other_name": ["Sutent, SU011248"], "criteria": "Inclusion Criteria: - Histologically confirmed advanced or metastatic Non-Small Cell Lung Cancer that cannot be cured with surgery, radiation, or combination thereof - No more than 2 prior chemotherapy treatments including treatment with a platinum containing therapy - Evidence of measurable disease by radiographic technique - Male or Female, 18 years or older - ECOG performance status of 0 or 1 - Resolution of all acute toxicities of prior therapies - Adequate organ function Exclusion Criteria: - Major surgery or radiation therapy within 4 weeks - Severe hemorrhage within 4 weeks - Previous treatment with anti-angiogenesis agents - Diagnosis of second malignancy within last five 5 years - History of or known brain metastases, spinal cord compression, or carcinomatous meningitis - Known HIV - Serious acute or chronic illness - Current treatment on another clinical trial - Pregnant or breastfeeding", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Non-small cell lung cancer, carcinoma, sunitinib, Phase 2", "mesh_term": ["Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Sunitinib"], "id": "NCT00092001"}